AngioDynamics (NASDAQ:ANGO) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

AngioDynamics, Inc. (NASDAQ:ANGO)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $11.95 and traded as high as $16.05. AngioDynamics shares last traded at $15.82, with a volume of 335,653 shares changing hands.

Analyst Ratings Changes

ANGO has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Stock Up 1.0%

The company has a market cap of $653.84 million, a price-to-earnings ratio of -18.18 and a beta of 0.33. The firm has a 50 day moving average price of $13.73 and a two-hundred day moving average price of $11.95.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insider Activity

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in AngioDynamics during the second quarter worth $49,480,000. Millennium Management LLC boosted its position in AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the last quarter. Kotler Kevin bought a new stake in AngioDynamics during the fourth quarter valued at $21,997,000. Armistice Capital LLC grew its holdings in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares during the period. Finally, Weber Capital Management LLC ADV acquired a new stake in AngioDynamics during the 4th quarter worth about $17,978,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.